Higher Early Exposure and Greater Early Glucose-lowering Effect with Faster-Acting Insulin Aspart vs. Insulin Aspart in Japanese Patients with T1D

被引：0
|
作者：
Shiramoto, Masanari
Nishida, Tomoyuki
Hansen, Ann Kathrine
Haahr, Hanne
机构：
来源：
DIABETES | 2015年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
983-P
引用
收藏
页码：A249 / A249
页数：1
相关论文
共 50 条
  • [31] Greater early postprandial suppression of endogenous glucose production and higher initial glucose disappearance is achieved with fast-acting insulin aspart compared with insulin aspart
    Basu, Ananda
    Pieber, Thomas R.
    Hansen, Ann K.
    Sach-Friedl, Stefanie
    Erichsen, Lars
    Basu, Rita
    Haahr, Hanne
    [J]. DIABETES OBESITY & METABOLISM, 2018, 20 (07): : 1615 - 1622
  • [32] Greater early postprandial suppression of endogenous glucose production is achieved with fast-acting insulin aspart compared to insulin aspart
    Pieber, T. R.
    Basu, A.
    Hansen, A. K.
    Sach-Friedl, S.
    Thomsen, K. M. D.
    Basu, R.
    Haahr, H.
    [J]. DIABETOLOGIA, 2017, 60 : S315 - S315
  • [33] Double-blind mealtime faster-acting insulin aspart improves glycaemic control with superior reduction in postprandial glucose excursions vs insulin aspart in type 1 diabetes: onset® 1
    Russell-Jones, D.
    Bode, B. W.
    De Block, C.
    Franek, E.
    Heller, S.
    Mathieu, C.
    Philis-Tsimikas, A.
    Rose, L.
    Woo, V.
    Osterskov, A. B.
    Graungaard, T.
    Bergenstal, R. M.
    [J]. DIABETOLOGIA, 2016, 59 : S6 - S6
  • [34] Pharmacological properties of faster-acting insulin aspart vs insulin aspart in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion: A randomized, double-blind, crossover trial
    Heise, Tim
    Zijlstra, Eric
    Nosek, Leszek
    Rikte, Tord
    Haahr, Hanne
    [J]. DIABETES OBESITY & METABOLISM, 2017, 19 (02): : 208 - 215
  • [35] Insulin degludec/insulin aspart in Japanese patients with type 1 diabetes mellitus: Distinct prandial and basal glucose-lowering effects
    Haahr, Hanne
    Sasaki, Tomio
    Bardtrum, Lars
    Ikushima, Ippei
    [J]. JOURNAL OF DIABETES INVESTIGATION, 2016, 7 (04) : 574 - 580
  • [36] Faster-Acting Insulin Aspart vs. Insulin Aspart as Part of Basal-Bolus Therapy Improves Postprandial Glycemic Control in Uncontrolled T2D in the Double- Blinded Onset® 2 Trial
    Bowering, Keith
    Case, Christopher
    Harvey, John
    Reeves, Michael
    Sampson, Mike
    Strzinek, Robert
    Bretler, Ditte-Marie
    Bang, Rikke Beck
    Bode, Bruce W.
    [J]. DIABETES, 2016, 65 : A63 - A63
  • [37] Double-blind mealtime faster-acting insulin aspart vs insulin aspart in basal-bolus improves glycaemic control in Type 1 diabetes: the onset 1 trial
    Russell-Jones, D.
    Bode, B. W.
    De Block, C.
    Franek, E.
    Heller, S.
    Mathieu, C.
    Philis-Tsimikas, A.
    Rose, L.
    Woo, V.
    Osterskov, A. B.
    Graungaard, T.
    Bergenstal, R.
    [J]. DIABETIC MEDICINE, 2017, 34 : 8 - 8
  • [38] PROJECTED LONG-TERM OUTCOMES IN PATIENTS WITH TYPE 1 DIABETES MELLITUS TREATED WITH FASTER-ACTING INSULIN ASPART VERSUS CONVENTIONAL INSULIN ASPART IN THE UK SETTING
    Russell-Jones, D.
    Buchs, S.
    Jensen, M. M.
    Hunt, B.
    Valentine, W. J.
    Heller, S.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A671 - A671
  • [39] Compatibility and safety of faster-acting insulin aspart used in continuous subcutaneous insulin infusion therapy in patients with type 1 diabetes
    Zijlstra, Eric
    Demissie, Marek
    Graungaard, Tina
    Heise, Tim
    Nosek, Leszek
    Bode, Bruce W.
    [J]. CLINICAL ENDOCRINOLOGY, 2017, 86 : 46 - 46
  • [40] Faster-acting insulin aspart: faster offset of exposure and action in addition to faster onset in subjects with type 1 diabetes using continuous subcutaneous insulin infusion
    Zijlstra, E.
    Heise, T.
    Nosek, L.
    Rikte, T.
    Haahr, H.
    [J]. DIABETOLOGIA, 2016, 59 : S98 - S99
12345